Region Norrbotten — Clinical Trial Site

28 Registered trials

10 Currently recruiting

Organisation

Region Norrbotten

Location

Lulea, Sweden

Identifier

ORG-100043469

Address

Robertsviksgatan 7, Lulea Domkyrkofors., 972 41, Sweden

Departments

-
7203: Medicinkliniken
9504: Hematologisk dagvård, Medicinkliniken, Sunderby sjukhus, 97180 Luleå
AnOpIVA, Sunderby sjukhus
Arvidsjaurs hälsocentral, 933 83 Arvidsjaur
Department of anesthesiology and intensive care medicin
Department of hematology
Department of Medicine
Hematology
Infektionskliniken, Sunderby sjukhus, Sjukhusvägen 10, 971 80 Luleå
Laponia hälsocentral
Laponia hälsocentral, Källgatan 14, 982 82 Gällivare
Lungkliniken Sunderby sjukhus
Med Rehabkliniken Piteå sjukhus
Medicin och rehabkliniken Kalix
Medicine
Medicinkliniken
Njursektionen Sunderby sjukhus
Oncology
Region Norrbotten
Sunderby Hospital, Sjukhusvägen 10, 971 80 Luleå, Department of Obstetrics and Gyneacology
Sunderby Hospital, Sjukhusvägen 10, 97180 Luleå, hemat dept
Sunderby sjukhus
Sunderby sjukhus avd 47
Sunderby sjukhus, Hematologisk dagvård, Nya psykiatrihuset plan 4, Sjukhusvägen 10, 971 80 Luleå
Sunderby sjukhus, Medicinkliniken
Sunderby sjukhus, Sjukhusvagen 10, 971 80 Lulea, Department of Hematology
Surgical Department

Clinical trials at this site (28)

Search interface

ALASCCA-A randomized double-blind placebo-controlled study with ASA treatment in colorectal cancer patients with mutations in the PI3K signa… Pending

2024-513778-23-00 Colon and rectal cancer tumor stage II-III, tumor with 5
SGLT2 inhibitor or metformin as standard treatment in early type 2 diabetes (SMARTEST) Pending

2024-516228-33-00 Type 2 Diabetes 6
Postoperative recovery with the addition of long-acting NK1- and 5-HT3 receptor antagonists as prophylaxis for post-operative nausea and vom… Pending

2025-522529-36-00 Post-operative nausea and vomiting (PONV) 5
LOWOX Recruiting

2024-513117-12-00 Surgery under general anesthesia 11 2025-01-16
Concomitant HPV vaccination and HPV screening for rapid elimination of HPV infection and cervical cancer in Sweden Recruiting

2024-518857-41-00 HPV infection and related diseases, such as cervical in 6 2024-11-29
A study to learn more about how well sevabertinib works and how safe it is compared with standard treatment, in participants who have advanc… Recruiting

2024-511319-91-00 Advanced non-small cell lung cancer with HER2 (ERBB2) m 5 2024-10-23
Iberdomide Manteinance Versus Lenalidomide Manteinance Therapy Following Autologous Stem Cell Transplant in Participants with NDMM Recruiting

2022-501515-14-00 Newly Diagnosed Multiple Myeloma (NDMM) 5 2023-09-29
Alternative antibiotics to multidrug-resistant UTIs Recruiting

2024-513294-41-00 Urinary tract infection and/or bacteremia caused by ext 6 2023-04-17
SACK Recruiting

2022-501600-10-00 Atrial fibrillation and Chronic Kidney Disease stage 5 5 2023-02-07
OPTION – OutPatienT InductiON: Labour induction in an outpatient setting - a multicentre randomized controlled trial Recruiting

2023-507164-39-00 Induction of labour 6 2021-12-01
The SANT-study - A randomized controlled clinical trial of Streptococcus group A-negative acute tonsillitis in primary health care - a compa… Recruiting

2023-508542-18-00 Tonsilitis 6 2019-09-02
Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736). An open label randomized phase II trial with durvalumab following Stereotacti… Ended

2024-512439-54-01 Non-small cell lung cancer (NSCLC) 4 2024-07-24
EVOLVE-MI Ended

2023-509268-26-00 Dyslipidemia 6 2024-01-08
International treatment-extension study in adult participants with multiple myeloma and who have derived clinical benefit from isatuximab Ended

2023-507180-19-00 Cancer 4 2023-04-05
This study is to find out about the Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in… Ended

2023-505628-67-00 Relapsed and Refractory Follicular Lymphoma 5 2022-10-28
Acalabrutinib and rituximab in elderly patients with untreated mantle cell lymphoma (ALTAMIRA) Ended

2023-509864-96-00 Mantle Cell Lymphoma (MCL) 4 2021-12-07
A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab… Ended

2022-500439-35-00 treatment-naive chronic lymphocytic leukemia 5 2021-02-11
POLAR BEAR Ended

2022-502887-19-00 Diffuse Large B-Cell Lymphoma 5 2020-08-18
HEAT-AML (Hydroxyurea-Enhanced Ara-C Treatment of Adult Acute Myeloid Leukaemia): A clinical study to assess whether addition of hydroxyurea… Ended

2023-509019-97-00 Newly diagnosed acute myeloid leukaemia (AML) in patien 9 2019-07-15
A STUDY OF EFFICACY AND SAFETY OF LONG-ACTING LOW DOSE ROPEGINTERFERON IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH BOSUTINIB FROM… Ended

2024-517417-32-00 CHRONIC MYELOID LEUKEMIA 4 2018-11-22
A Phase 3 Study of Zanubrutinib (BGB-3111) Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocyt… Ended

2023-509976-40-00 Untreated Chronic Lymphocytic Leukemia or Small Lymphoc 5 2018-05-28
A Randomized, Open-label, Phase 3 study of the Combination of Ibrutinib plus Venetoclax versus Chlorambucil plus Obinutuzumab for the First-… Ended

2023-503469-49-00 Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic L 5 2018-04-19
ENRICH - Randomised, open label study of Rituximab/Ibrutinib vs Rituximab/Chemotherapy in older patients with untreated mantle cell lymphoma Ended

2024-514275-18-00 Mantle Cell Lymphoma (MCL) 10 2017-12-06
A prospective phase II study to assess the minimal residual disease after ixazomib plus lenalidomide plus dexamethasone (IRd) treatment for … Ended

2024-517321-99-00 Myeloma multiplex 4 2016-08-01